Latest News

Uncategorized

ESMO 2019: Docetaxel for Hormone-Naïve Prostate Cancer: Results from Long-Term Follow-Up of Metastatic (M1) Patients in the STAMPEDE Randomized Trial and Sub Group Analysis by Metastatic Burden – Medical Oncologist Perspective

Barcelona, Spain (UroToday.com) Nick James, PhD, presented results from the STAMPEDE trial for the addition of docetaxel to first-line hormonal therapy for patients with metastatic (M1) hormone-naïve prostate cancer (mHNPC). In 2015, the CHAARTED study demonstrated that adding docetaxel to standard of care androgen deprivation therapy (ADT) in men initiating treatment for mHNPC prolongs survival […]

Uncategorized

ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-Analysis – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows certain adverse pathologic features (adjuvant radiotherapy) or if they experience biochemical recurrence (salvage radiotherapy). Given prior conflicting clinical trial data that utilized outdated definitions and assays for biochemical recurrence, […]

Uncategorized

ESMO 2019: Timing of Radiotherapy after Radical Prostatectomy: First Results from the RADICALS Radiation Therapy Randomised Controlled Trial

Barcelona, Spain (UroToday.com) Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows certain adverse pathologic features (adjuvant radiotherapy or aRT) or if they experience biochemical recurrence (early salvage radiotherapy or eSRT). Two prior trials randomizing men with high-risk prostatectomy features to adjuvant […]

Uncategorized

ESMO 2019: Invited Discussant – An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial – A Medical Oncologist’s Perspective

Barcelona, Spain (UroToday.com) Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows certain adverse pathologic features (adjuvant radiotherapy or aRT) or if they experience biochemical recurrence (salvage radiotherapy or eSRT). Given conflicting clinical trial data that utilized outdated definitions and assays for […]

Uncategorized

ESMO 2019: Invited Discussant – An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial

Barcelona, Spain (UroToday.com) In this session, Dr. Karim Fizazi discussed the prior two sessions including 1.) updated results from the Phase 3 SPARTAN study of apalutamide (APA) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in men with high-risk non metastatic castration-resistant prostate cancer (nmCRPC), and 2.) docetaxel for metastatic hormone-naïve prostate cancer (mHNPC) […]

Uncategorized

ESMO 2019: Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study

Barcelona, Spain (UroToday.com) The SPARTAN study is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial investigating the efficacy and safety of apalutamide (APA) in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Patients with nmCRPC were randomized to APA + androgen deprivation therapy (ADT) or placebo (PBO) + ADT. Initial published analysis with a median follow-up […]

Uncategorized

ESMO 2019: RADICALS and ARTISTIC Discussion: Thoughts from a Radiation Oncologist

Barcelona, Spain (UroToday.com) At the ESMO 2019 prostate cancer session, RADICALS – a phase III trial of adjuvant radiotherapy vs observation + salvage radiotherapy after radical prostatectomy – reported no benefit of adjuvant radiotherapy, and ARTISTIC – a prospective meta-analysis of RADICALS, RAVES, and GETUG-AFU 17 – reported a pooled hazard ratio also demonstrating no benefit […]

Uncategorized

ESMO 2019: Timing of Radiotherapy After Radical Prostatectomy: First Results from the RADICALS Radiotherapy Randomized Controlled Trial

Barcelona, Spain (UroToday.com) The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. Supporters of adjuvant radiotherapy suggest that earlier treatment may be more effective, whereas those that support salvage radiotherapy suggest that this approach avoids unnecessary treatment. There are conflicting results from previous adjuvant radiotherapy trials: among 425 men with pT3N0M0 prostate cancer […]

Uncategorized

ESMO 2019: Treatment Intensification in Advanced Prostate Cancer: SPARTAN, STAMPEDE, and Others

Barcelona, Spain (UroToday.com) At the Friday session at the 2019 European Society for Medical Oncology annual meeting (ESMO) meeting on prostate cancer, Karim Fizazi, MD, Ph.D., provided a discussion of the updated docetaxel STAMPEDE trial and updated SPARTAN trial, which included overall survival (OS) data. Dr. Fizazi highlighted that apalutamide was associated with a 25% reduction […]

Uncategorized

ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-analysis

Barcelona, Spain (UroToday.com) There are three randomized trials, RADICALS (ISRCTN40814031),1 GETUG-AFU 17 (NCT00667069) and RAVES (NCT00860652); recently presented at ASTRO 2019, that have compared adjuvant radiotherapy with a policy of salvage radiotherapy for PSA failure after radical prostatectomy for men with localized prostate cancer. However, these trials have limited power for long-term outcomes. At the ESMO […]

X